Jing Cai-Xia, Feng Yu, Cao Xia, Xu Cai-Gang
Department of Hematology/Hemaology Research Laboratory, West China Hospital, Sichuan University, Chengdu 610041, China.
Department of Hematology, Affiliated Hospital of Southwest Medical University, Luzhou 646000, China.
Sichuan Da Xue Xue Bao Yi Xue Ban. 2020 May;51(3):355-360. doi: 10.12182/20200560605.
Investigate the expression of SRY-related HMG box 11 (SOX11) and paired box domain 5 (PAX5) in patients with mantle cell lymphoma (MCL) and analyze the relationship between them and their clinical significance.
Seventy-six formalin-fixed paraffin-embedded (FFPE) samples of patients who were diagnosed with MCL from January 2012 to August 2017 were collected．Fifty-six FFPE samples from patients with diffuse large B cell lymphoma (DLBCL), thirty-eight FFPE samples from patients with follicular lymphoma (FL) and nine FFPE samples from patients with Burkitt's lymphoma (BL) were used as control groups. Real-time quantitative PCR (qRT-PCR) and immunohistochemistry were used to detect the mRNA and protein expressions of SOX11 and PAX5. The association between expressions of SOX11 and PAX5 in patients with MCL was analyzed. On the basis of the median H score of SOX11 and PAX5 protein expressions in patients with MCL, they were divided into high and low expression group, and the relationship between the different groups and patients' clinical characteristics and prognosis were analyzed.
The different mRNA expression levels of 11 and 5 in different lymphoma tissues were statistically significant ( <0.01). The mRNA expression levels of 11 and 5 in MCL group were higher than those of the control groups, and the differences of those between MCL and DLBCL or FL were statistically significant ( <0.01). However, the differences of those between MCL and BL were not significant ( >0.05). The expression level of SOX11 protein was also higher than those of the control groups ( <0.000 1). However, there was no significant difference in PAX5 protein expression level between the MCL group and the control group, nor the expression levels of SOX11 and PAX5 genes and proteins among the control groups ( >0.05). By analyzing the samples from patients with MCL, we observed a positive relevance between SOX11 and PAX5 both in mRNA expression level ( =0.714, <0.000 1) and protein expression level ( =0.407, =0.01). There was no difference in clinical characteristics and overall survival between the high and low expression group.
In MCL, there was a positive relevance between the expressions of SOX11 and PAX5. The expression of SOX11 or PAX5 alone has no significant effect on the prognostic stratification of MCL patients.
研究SRY相关高迁移率族蛋白盒11（SOX11）和配对盒结构域5（PAX5）在套细胞淋巴瘤（MCL）患者中的表达情况，并分析它们之间的关系及其临床意义。
收集2012年1月至2017年8月确诊为MCL患者的76例福尔马林固定石蜡包埋（FFPE）样本。将弥漫性大B细胞淋巴瘤（DLBCL）患者的56例FFPE样本、滤泡性淋巴瘤（FL）患者的38例FFPE样本和伯基特淋巴瘤（BL）患者的9例FFPE样本作为对照组。采用实时定量PCR（qRT-PCR）和免疫组织化学检测SOX11和PAX5的mRNA和蛋白表达。分析MCL患者中SOX11和PAX5表达之间的相关性。根据MCL患者中SOX11和PAX5蛋白表达的H评分中位数，将其分为高表达组和低表达组，并分析不同组与患者临床特征及预后的关系。
不同淋巴瘤组织中SOX11和PAX5的mRNA表达水平差异有统计学意义（P<0.01）。MCL组中SOX11和PAX5的mRNA表达水平高于对照组，MCL与DLBCL或FL之间的差异有统计学意义（P<0.01）。然而，MCL与BL之间的差异无统计学意义（P>0.05）。SOX11蛋白表达水平也高于对照组（P<0.0001）。然而，MCL组与对照组之间PAX5蛋白表达水平无显著差异，对照组之间SOX11和PAX5基因及蛋白表达水平也无显著差异（P>0.05）。通过分析MCL患者的样本，我们观察到SOX11和PAX5在mRNA表达水平（r=0.714，P<0.0001）和蛋白表达水平（r=0.407，P=0.01）上均呈正相关。高表达组和低表达组在临床特征和总生存期方面无差异。
在MCL中，SOX11和PAX5的表达呈正相关。单独SOX11或PAX5的表达对MCL患者的预后分层无显著影响。
